Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of ...

Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion-positive NSCLC, signaling a ...

Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

LIBRETTO-432 shows statistically significant event-free survival benefit in RET fusion-positive NSCLC after initial therapy.

Eli Lilly operates in the healthcare sector as a global pharmaceutical manufacturer with commercial medicines and a broad research portfolio across immunology, oncology, and metabolic health. Eli ...

Lilly's phase 3 LIBRETTO-432 trial of Retevmo an adjuvant therapy in early-stage RET fusion-positive lung cancer meets its primary endpoint: Indianapolis Tuesday, February 17, 202 ...

An expert discusses the recent approval for Retevmo for RET-positive pediatric thyroid cancer and ongoing research for this patient population. The recent Food and Drug Administration (FDA) approval ...

Harper Hubbeling, MD; Noura Choudhury, MD; Jessica Flynn, BS; Zhigang Zhang, PhD; Christina Falcon, MPH; Valerie W. Rusch, MD; Bernard J. Park, MD; Etay Ziv, MD, PhD ...

CARLSBAD, Calif.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in ...

Life-cycle health technology assessment for precision oncology. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.